Friday, October 23, 2015 7:06 PM
|
DIRECT-MS shared a link.
Once tapped as a likely blockbuster, Roche and Biogen Idec have opted to kill their ambitious late-stage development program of ocrelizumab as a treatment for rheumatoid arthritis. Researchers had
|